| Market Capitalization (Millions $) |
1,528 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
297 |
| Revenues (TTM) (Millions $) |
384 |
| Net Income (TTM) (Millions $) |
-9 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for patients with devastating diseases and unmet medical needs. The company was founded in 2015 and is based in Hamilton, Bermuda.
The company has a portfolio of product candidates targeting multiple indications, including autoimmunity, inflammation, and oncology. These product candidates are based on the company's expertise in immune and inflammatory pathways.
Kiniksa's lead product candidate is Rilonacept, a recombinant fusion protein that blocks interleukin-1 alpha and beta, which are cytokines that play a significant role in inflammation. Rilonacept is currently in Phase III clinical trials for the treatment of recurrent pericarditis, a rare autoinflammatory disease affecting the lining of the heart.
The company's other product candidates include KPL-716, a monoclonal antibody that targets the CD40 ligand, which is a critical mediator of inflammation in multiple autoimmune diseases. KPL-404 is another product candidate being developed for the treatment of prurigo nodularis, a chronic itch disorder.
Kiniksa Pharmaceuticals operates with a focus on research and development, seeking out new methodologies to develop new therapeutics. This includes collaborating with various research institutions and universities, as well as partnering with other biotechnology and pharmaceutical companies.
The company's management team consists of industry veterans with extensive experience in drug discovery, development, and commercialization. Furthermore, the company follows a well-defined set of values and principles, promoting ethical behavior and corporate social responsibility.
In summary, Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company that is committed to discovering and developing therapeutics for patients with unmet medical needs. With a strong pipeline of product candidates and a focus on research and development, the company has positioned itself as a leader in the biotechnology industry. Additionally, the company operates with a strong sense of corporate social responsibility, promoting ethical behavior and transparency in its operations.
Company Address: 23 Old Bond Street, Floor 3 London 0
Company Phone Number: 431-9100 Stock Exchange / Ticker: NASDAQ KNSA
|
0.08%